[연기금 K바이오 재편]① 실적 보이는 CDMO·플랫폼주 '투자 확대'

South Korea's National Pension Fund is strategically reorienting biotech investments toward companies with proven business models (CDMO services) and scalable technology platforms, signaling institutional confidence in the sector's commercialization maturity. This shift from speculative early-stage ventures to revenue-generating companies with validated technologies reflects biotech investment reaching institutional-grade standards. The capital reallocation could accelerate growth for Korean biotech platforms competing globally in RNA therapeutics and precision medicine.